Nott · Science (New York, N.Y.) 2019 · functional genomics and chromatin interactome study · n=?

Brain cell type-specific enhancer-promoter interactome maps and disease - risk association.

Cited 810 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench functional genomics and cellular assays on human brain cell types

PubMed 31727856 · doi:10.1126/science.aay0793 · record verified 2026-08-29

What was done

Noncoding regulatory regions (transcriptional enhancers and promoters) were mapped across major cell types of the human brain to construct cell-type-specific enhancer-promoter interactomes. These maps were used to integrate noncoding risk variants for psychiatric disorders and sporadic Alzheimer's disease with target genes. Functional validation was performed by deleting a microglia-specific enhancer harboring Alzheimer's disease risk variants and testing its effect on BIN1 expression in microglia, neurons, and astrocytes.

What was found

Psychiatric disorder risk variants mapped primarily to neuronal enhancers and promoters, whereas sporadic Alzheimer's disease variants localized predominantly to microglia enhancers. Targeted deletion of a microglia-specific enhancer containing Alzheimer's risk variants eliminated BIN1 expression in microglia, but did not alter BIN1 expression in neurons or astrocytes. The abstract does not report specific numerical metrics or statistical effect sizes.

Why it matters

These interactome maps connect noncoding disease variants to their functional target genes in specific brain cell types, establishing that Alzheimer's disease risk variants disproportionately alter microglial gene networks rather than general neuronal circuitry.

Limits

The abstract does not state the number of human brain samples or donors utilized, nor does it report quantitative values, error rates, or statistical significance metrics. In vitro deletion experiments are detailed for only one locus (BIN1), and findings rely on cellular model systems rather than in vivo clinical outcomes.

Cited by